ClinicalTrials.gg
RecruitingNCT07939633OMEGA3-FEMALEUpdated Nov 16, 2026

Effects of Omega-3 Supplementation on Motor Performance and Bone Turnover Markers in Women: A Pilot Study

An interventional study of Omega-3 Fatty Acid Supplementation and Placebo - MCT Oil in Motor Performance, Bone Turnover Markers and Bone Mineral Density, sponsored by Wroclaw University of Health and Sport Sciences. Recruiting at 1 site in Poland. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Wroclaw University of Health and Sport Sciences · Not applicable, Interventional, and Basic science

How we know

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The aim of this pilot study is to assess the effects of 10 weeks of omega-3 fatty acid supplementation on selected motor performance parameters, bone turnover markers, regulators of bone remodeling, and bone mineral density in female soccer players and women with low levels of physical activity. Changes in the erythrocyte omega-3 fatty acid profile, including EPA and DHA levels and the Omega-3 Index, will also be assessed, along with potential differences in response to supplementation between the two populations.

This will be an interventional, randomized, double-blind, placebo-controlled study. A total of 40 women aged 18-35 years will be enrolled: 20 female soccer players and 20 women with low levels of physical activity. Within each population, participants will be randomly allocated in a 1:1 ratio to the omega-3 supplementation or placebo group, yielding four parallel study groups. Over 10 weeks, participants assigned to omega-3 will take three capsules daily providing 1,677 mg of EPA and 687 mg of DHA. Participants assigned to placebo will take three capsules daily providing a total of 3,000 mg of MCT oil.

Assessments will be performed at three time points: T0 (baseline, before the start of supplementation), T1 (after 5 weeks of supplementation), and T2 (after 10 weeks of supplementation). Assessments will include handgrip strength, back muscle strength, lower-limb power assessed by vertical jump testing, bone turnover markers and regulators of bone remodeling, body composition and bone mineral density measured by DXA, the erythrocyte fatty acid profile, selected hormonal parameters, and dietary intake.

The effects of supplementation will be evaluated by assessing changes in the measured parameters at weeks 5 and 10 relative to baseline (T0). The magnitude of these changes will also be compared between the omega-3 and placebo groups, taking participants' level of physical activity into account.

Read the detailed description

Omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are involved in numerous physiological processes, including regulation of inflammatory responses and the functioning of skeletal muscle and bone tissue. However, scientific evidence regarding the effects of omega-3 supplementation on physical performance and bone metabolism remains inconclusive, particularly among physically active women. This pilot study will assess responses to a controlled supplementation intervention in female soccer players and women with low levels of physical activity.

The study is interventional, randomized, placebo-controlled, and double-blind. It will include 40 women aged 18-35 years: 20 female soccer players and 20 women with low levels of physical activity. Randomization will be conducted separately within each population in a 1:1 ratio, resulting in four groups: female soccer players receiving omega-3, female soccer players receiving placebo, women with low levels of physical activity receiving omega-3, and women with low levels of physical activity receiving placebo. Treatment allocation will remain concealed from participants, outcome assessors, and data analysts until study completion and database lock.

For 10 weeks, participants in the active supplementation groups will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily, providing 3,000 mg of concentrated fish oil, including 1,677 mg of EPA and 687 mg of DHA. Participants in the placebo groups will take three NOW Foods MCT Oil 1000 mg capsules daily, providing 3,000 mg of MCT oil. Supplement adherence and any adverse events will be monitored using participant records, contact with the research team, and counts of unused capsules.

Assessments will be conducted at three time points: T0 (baseline, before supplementation), T1 (after 5 weeks of supplementation), and T2 (after 10 weeks of supplementation). The T0 assessment will establish baseline values for the measured parameters, providing a reference for evaluating changes during the intervention. At each time point, motor performance will be assessed using handgrip strength, back muscle strength, and vertical jump tests. Body composition and bone mineral density will be assessed by dual-energy X-ray absorptiometry (DXA). Blood measurements will include the erythrocyte fatty acid profile and Omega-3 Index, estradiol and progesterone, and bone metabolism markers P1NP, CTX, OPG, RANKL, SOST, and DKK-1. Data on health status, menstrual cycle, hormonal contraception, physical activity, dietary intake, and anthropometry will also be collected.

The primary scientific aim is to assess the effects of omega-3 fatty acid supplementation compared with placebo on selected motor performance parameters, markers of bone turnover and remodeling, and bone mineral density. Intervention effects will be evaluated by comparing values at T1 and T2 with baseline values at T0, including comparisons between the omega-3 and placebo groups. Supplementary analyses will assess changes in EPA and DHA levels and potential differences in response between female soccer players and women with low levels of physical activity.

02

Conditions studied

  • Motor Performance
  • Bone Turnover Markers
  • Bone Mineral Density

Keywords

  • Omega-3 Fatty Acids
  • Eicosapentaenoic Acid (EPA)
  • Docosahexaenoic Acid (DHA)
  • Omega-3 Index
  • Female Soccer Players
  • Low Physical Activity
  • Muscle Strength
  • Lower-Limb Power
  • Bone Turnover Markers
  • Bone Mineral Density
  • Randomized Controlled Trial
03

In context

Lead sponsor

Wroclaw University of Health and Sport Sciences is the lead sponsor of 47 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female soccer players:

  • Female sex, age 18-35 years.
  • Regular sports training for more than 10 hours per week.
  • Active participation in league competitions.
  • No medical to participation.
  • No injury resulting in a training interruption longer than 2 weeks during the 3 months before the study.
  • Written to participate, undergo blood collection, and have laboratory tests performed.

Women with low levels of physical activity:

  • Female sex, age 18-35 years.
  • Physical activity below 150 minutes per week.
  • (BMI) between 18.5 and 24.9 kg/m².
  • No medical contraindications to participation.
  • Written informed consent to participate, undergo blood collection, and have laboratory tests performed.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding.
  • Use of supplements containing omega-3 fatty acids within the 3 months before the study.
  • Allergy or to fish, fish oil, gelatin, or other ingredients of the active supplement or placebo.
  • Diseases or use of medications that may substantially affect lipid metabolism, muscle function, or bone metabolism.
  • Neurological disorders.
  • Bleeding disorders or treatment considered by a physician to increase the risks associated with supplementation or blood sampling.
  • Injury or symptoms that prevent safe performance of motor tests.
  • Other identified during medical screening.
  • Failure to provide written to participate, undergo blood collection, and have the planned analyses performed.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Arm 1 - Female Soccer Players: Omega-3

    Female soccer players actively participating in league competitions and training for more than 10 hours per week will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily for 10 weeks.

    Dietary Supplement: Omega-3 Fatty Acid Supplementation

  • Placebo comparator
    Arm 2 - Female Soccer Players: Placebo

    Female soccer players actively participating in league competitions and training for more than 10 hours per week will take three NOW Foods MCT Oil 1000 mg capsules daily for 10 weeks.

    Dietary Supplement: Placebo - MCT Oil

  • Experimental
    Arm 3 - Women With Low Levels of Physical Activity: Omega-3

    Women with low levels of physical activity (less than 150 minutes per week) will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily for 10 weeks.

    Dietary Supplement: Omega-3 Fatty Acid Supplementation

  • Placebo comparator
    Arm 4 - Women With Low Levels of Physical Activity: Placebo

    Women with low levels of physical activity (less than 150 minutes per week) will take three NOW Foods MCT Oil 1000 mg capsules daily for 10 weeks.

    Dietary Supplement: Placebo - MCT Oil

Interventions

  • Dietary supplementOmega-3 Fatty Acid Supplementation

    Participants will take three softgel capsules daily for 10 weeks. The daily dose will provide 3,000 mg of concentrated fish oil containing 2,457 mg of omega-3 fatty acids, including 1,677 mg of EPA and 687 mg of DHA.

  • Dietary supplementPlacebo - MCT Oil

    Participants will take three softgel capsules daily for 10 weeks, providing 3,000 mg of MCT oil per day. The placebo contains neither EPA nor DHA.

06

What researchers measure

Primary outcomes

  1. Change in Handgrip Strength

    Handgrip strength will be assessed using a T.K.K. 5001 dynamometer (Takei Scientific Instruments) at T0, T1, and T2. Changes after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  2. Change in Back Muscle Strength

    Back muscle strength will be measured using a T.K.K. 5402 dynamometer (Takei Scientific Instruments) at T0, T1, and T2. Changes after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  3. Change in Vertical Jump Performance

    Lower-limb power will be assessed using vertical jump testing with the OptoJump system (Microgate) at T0, T1, and T2. Changes in vertical jump results after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: : T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  4. Change in Serum P1NP Concentration

    Serum concentrations of the N-terminal propeptide of type I procollagen (P1NP), a marker of bone formation, will be determined by ELISA at T0, T1, and T2. Changes in P1NP concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  5. Change in Serum CTX Concentration

    Serum concentrations of the C-terminal telopeptide of type I collagen (CTX), a marker of bone resorption, will be measured at T0, T1, and T2. Changes in CTX concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  6. Change in Bone Mineral Density

    Whole-body bone mineral density (BMD) will be assessed by DXA using a Lunar iDXA scanner (GE HealthCare) at T0, T1, and T2. Changes in BMD after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Secondary outcomes

  1. Change in Serum Osteoprotegerin Concentration

    Osteoprotegerin (OPG), a regulator of bone remodeling, will be measured in serum using ELISA at T0, T1, and T2. Changes in OPG concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  2. Change in Serum RANKL Concentration

    Receptor activator of nuclear factor kappa-B ligand (RANKL) will be measured in serum using ELISA at T0, T1, and T2. Changes in RANKL concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  3. Change in Serum Sclerostin Concentration

    Sclerostin (SOST) will be measured in serum using ELISA at T0, T1, and T2. Changes in SOST concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  4. Change in Serum DKK-1 Concentration

    Dickkopf-1 (DKK-1) protein will be measured in serum using ELISA at T0, T1, and T2. Changes in DKK-1 concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  5. Change in Erythrocyte EPA Content

    The proportion of eicosapentaenoic acid (EPA) in the erythrocyte fatty acid profile will be determined by gas chromatography with flame ionization detection (GC-FID) at T0, T1, and T2. Changes in EPA content after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  6. Change in Erythrocyte DHA Content

    The proportion of docosahexaenoic acid (DHA) in the erythrocyte fatty acid profile will be determined by gas chromatography with flame ionization detection (GC-FID) at T0, T1, and T2. Changes in DHA content after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  7. Change in Omega-3 Index

    The Omega-3 Index will be calculated from the combined proportion of EPA and DHA in the erythrocyte fatty acid profile at T0, T1, and T2. Changes in the Omega-3 Index after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

  8. Change in the Erythrocyte Omega-6 to Omega-3 Ratio

    The omega-6 to omega-3 fatty acid ratio will be derived from the erythrocyte fatty acid profile measured by GC-FID at T0, T1, and T2. Changes in the omega-6 to omega-3 ratio after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Other outcomes

  1. Change in Dietary Intake

    Dietary intake will be assessed using a 72-item food frequency questionnaire and a 7-day food diary, including the intake of omega-3 fatty acids. Assessments will be conducted at T0, T1, and T2. Changes in dietary intake and omega-3 fatty acid consumption after 5 and 10 weeks of supplementation relative to baseline will be analyzed.

    Time frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Larrosa M, Gil-Izquierdo A, Gonzalez-Rodriguez LG, Alferez MJM, San Juan AF, Sanchez-Gomez A, Calvo-Ayuso N, Ramos-Alvarez JJ, Fernandez-Lazaro D, Lopez-Grueso R, Lopez-Leon I, Moreno-Lara J, Dominguez-Balmaseda D, Illescas-Quiroga R, Cuenca E, Lopez T, Montoya JJ, Rodrigues-de-Souza DP, Carrillo-Alvarez E, Casado A, Rodriguez-Donate B, Porta-Oliva M, Santiago C, Iturriaga T, De Lucas B, Solaesa AG, Montero-Lopez MDP, Benitez De Gracia E, Veiga-Herreros P, Munoz-Lopez A, Orantes-Gonzalez E, Barbero-Alvarez JC, Cabeza-Ruiz R, Carnero-Diaz A, Sospedra I, Fernandez-Galvan LM, Martinez-Sanz JM, Martin-Almena FJ, Perez M, Guerra-Hernandez EJ, Lopez-Samanes A, Sanchez-Oliver AJ, Dominguez R. Nutritional Strategies for Optimizing Health, Sports Performance, and Recovery for Female Athletes and Other Physically Active Women: A Systematic Review. Nutr Rev. 2025 Mar 1;83(3):e1068-e1089. doi: 10.1093/nutrit/nuae082. PubMed 38994896 ↗
  • Gao J, Xie C, Yang J, Tian C, Zhang M, Lu Z, Meng X, Cai J, Guo X, Gao T. The Effects of n-3 PUFA Supplementation on Bone Metabolism Markers and Body Bone Mineral Density in Adults: A Systematic Review and Meta-Analysis of RCTs. Nutrients. 2023 Jun 19;15(12):2806. doi: 10.3390/nu15122806. PubMed 37375709 ↗
  • Dou Y, Wang Y, Chen Z, Yu X, Ma D. Effect of n-3 polyunsaturated fatty acid on bone health: A systematic review and meta-analysis of randomized controlled trials. Food Sci Nutr. 2021 Nov 29;10(1):145-154. doi: 10.1002/fsn3.2655. eCollection 2022 Jan. PubMed 35035917 ↗
  • Fernandez-Lazaro D, Arribalzaga S, Gutierrez-Abejon E, Azarbayjani MA, Mielgo-Ayuso J, Roche E. Omega-3 Fatty Acid Supplementation on Post-Exercise Inflammation, Muscle Damage, Oxidative Response, and Sports Performance in Physically Healthy Adults-A Systematic Review of Randomized Controlled Trials. Nutrients. 2024 Jun 27;16(13):2044. doi: 10.3390/nu16132044. PubMed 38999792 ↗
  • Jager R, Heileson JL, Abou Sawan S, Dickerson BL, Leonard M, Kreider RB, Kerksick CM, Cornish SM, Candow DG, Cordingley DM, Forbes SC, Tinsley GM, Bongiovanni T, Cannataro R, Campbell BI, Arent SM, Stout JR, Kalman DS, Antonio J. International Society of Sports Nutrition Position Stand: Long-Chain Omega-3 Polyunsaturated Fatty Acids. J Int Soc Sports Nutr. 2025 Dec;22(1):2441775. doi: 10.1080/15502783.2024.2441775. Epub 2025 Jan 15. PubMed 39810703 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared with external researchers or deposited in public repositories, even after removal of direct identifiers. Access to the data will be restricted to authorized members of the research team. Study results will be published only in aggregate form, without disclosing participants' identities.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Oct 27, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Feb 28, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939633
Lead sponsor
Wroclaw University of Health and Sport Sciences
Responsible party
Aleksandra Sarachman (Phd Students, Wroclaw University of Health and Sport Sciences) — Principal investigator
First posted
Nov 16, 2026
Start date
Oct 27, 2026 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Aleksandra Aneta Sarachman, MSc
Contact
aleksandra.sarachman@awf.wroc.pl
+48 882 521 877
Anna Książek, PhD, DSc
study chair · Department of Biological Principles of Physical Activity Wroclaw University of Health and Sport Sciences, Poland 35 Paderewskiego Avenue, 51-612 Wrocław,

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion